Answers are grounded in this paper and cite their sources.
Purpose: It is estimated that 350 to 400 million individuals worldwide have chronic hepatitis B virus (HBV) infection, and 500,000 to 1 million HBsAg carriers die each year. In the United States, currently approved treatment options for CHB include interferon alfa-2b, lamivudine, ADV, entecavir, peginterferon alfa-2a, and telbivudine. The rates of HBeAg seroconversion after one year of therapy with these agents are low, ranging from 12% to 27%, and the rates of HBsAg loss or seroconversion are usually zero except for interferon and peginterferon, which achieve loss of HBsAg in 3% to 8% of cases. It has been shown that NTZ is a potent inhibitor of HBV in cell culture assays, and combination with other antiviral agents including lamivudine and ADV shows moderate synergistic effects (Korba BE, Antivir. Res. 2008;77:56). In addition, these in vitro studies demonstrate that NTZ induces reduction in HBeAg and HBsAg. In a prior case report, NTZ treatment of a patient with HBeAg-positive CHB for 24 weeks resulted in suppression of serum HBV DNA to undetectable, normalization of alanine aminotransferase (ALT) levels, and loss of HBeAg (Rossignol JF, Gastroenterology. 2006;130:A848). Methods: Case #1 is a 17-year-old male with HBeAg-positive CHB and baseline HBV DNA level of 310,000 copies/mL, ALT 25 IU/mL, and grade 3/18 inflammation and stage 1/6 fibrosis on biopsy. He was treated with NTZ 500 mg bid through month 5, was off treatment for 3 months secondary to elevated ALT levels, and then was treated with 500 mg/d through month 24. Case #2 is a 60-year-old male with HBeAg-positive CHB who received lamivudine 100 mg/d for 2 years and then ADV 10 mg/d for 1 year without response; NTZ 500 mg bid was then added to ADV 10 mg/d and combination therapy continued for two years. When NTZ was added to ADV, baseline serum HBV DNA was 8,380,000 IU/mL and ALT was 82 IU/L. Results: Case #1 first developed undetectable HBV DNA at month 13, negative HBeAg at month 12, and negative HBsAg at month 21. Case #2, after 1 year of dual therapy with NTZ and ADV, had decrease in HBV DNA to 71,000 IU/ml and ALT to 61 IU/L. After 2 years of dual therapy, HBV DNA was undetectable, ALT was 19 IU/L, and HBeAg and HBsAg were negative. Case #2 also developed antibody to HBsAg (anti-HBs), confirming that he underwent HBsAg seroconversion. Conclusion: These two case reports provide further clinical evidence of antiviral activity of NTZ in patients with CHB and suggest that NTZ may achieve higher rates of HBeAg and HBsAg loss and seroconversion than current oral antiviral agents. Randomized, controlled trials are needed to confirm these results in a large number of subjects with CHB, and these studies have been initiated.
No takes yet. Share an insight, caveat, or question.
Kolozsi et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: